跳转至内容
Merck
CN
  • Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.

Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.

Rheumatology (Oxford, England) (2009-08-05)
Takeo Sato, Shigeko Inokuma, Akira Sagawa, Takemasa Matsuda, Tamiko Takemura, Takeshi Otsuka, Yukihiko Saeki, Tsutomu Takeuchi, Tetsuji Sawada
摘要

To elucidate the factors associated with poor prognosis of LEF-induced lung injury in patients with RA. The background and clinical and laboratory features of LEF-induced lung injury were examined and compared between patients who died of and who recovered from it. Among 22 patients who developed LEF-induced lung injury, 9 died of and 13 recovered from it. The patients who died tended to have pre-existing interstitial pneumonia (8/9 vs 6/13, P = 0.07). The loading and maintenance doses, serum concentration of the LEF metabolite A771726 and administration period did not differ between the groups. Patients who died had more frequently hypoxaemia of <60 Torr and mechanical ventilation, and had a high serum CRP level (19.3 +/- 9.4 vs 10.1 +/- 8.1 mg/dl, P = 0.03) and a low albumin level (2.7 +/- 0.6 vs 3.3 +/- 0.5 g/dl, P = 0.03) at the lung injury onset. The peripheral blood lymphocyte count decreased in both groups at the lung injury onset, and it remained low until fatal outcome, in contrast to a re-increase upon recovery (406 +/- 394 vs 1203 +/- 399/microl, P = 0.006). The main histopathological finding in two autopsied patients was diffuse alveolar damage, in contrast to the alveolitis observed in a biopsied patient who recovered. Pre-existing interstitial pneumonia, extremely high serum CRP and low albumin levels, severe hypoxaemia and mechanical ventilation indicated poor prognosis. Peripheral blood lymphocytopenia developed in association with lung injury, and a sustained low lymphocyte count indicated a fatal outcome.

材料
货号
品牌
产品描述

USP
Leflunomide Related Compound B, United States Pharmacopeia (USP) Reference Standard